GlassScriptPhysician profile
Laurie Bain
NPI 1134125834
$5,970.66
in general payments reported to CMS, 2019-2025
26 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $408 · 2021: $617 · 2022: $1,070 · 2023: $1,100 · 2024: $1,047 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.89 | 2019-2025 | Skyrizi, Rinvoq |
| Incyte Corporation | $524.05 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $473.71 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $400.13 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $336.94 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $335.99 | 2019-2025 | Cabtreo, Jublia |
| Amgen INC. | $320.56 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $307.09 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $296.49 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Novartis Pharmaceuticals Corporation | $278.70 | 2019-2025 | |
| Genzyme Corporation | $222.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.19 | 2022-2024 | Sotyktu |
| Ucb, INC. | $155.58 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $142.00 | 2021-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $136.24 | 2019-2024 | Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $124.42 | 2023-2025 | Zoryve |
| Almirall LLC | $115.49 | 2021-2024 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $102.30 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.55 | 2023-2025 | Spevigo, Cyltezo |
| Genentech USA, INC. | $68.89 | 2021-2022 | |
| Epi Health, LLC | $45.86 | 2022 | |
| Biofrontera INC. | $36.81 | 2022 | |
| Allergan, INC. | $24.45 | 2020 | |
| Verrica Pharmaceuticals INC. | $18.69 | 2023 | Ycanth |
| Celgene Corporation | $12.89 | 2019 | |
| Ani Pharmaceuticals, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.